JP2009518422A - ミオスタチン・アンタゴニストの使用 - Google Patents

ミオスタチン・アンタゴニストの使用 Download PDF

Info

Publication number
JP2009518422A
JP2009518422A JP2008544468A JP2008544468A JP2009518422A JP 2009518422 A JP2009518422 A JP 2009518422A JP 2008544468 A JP2008544468 A JP 2008544468A JP 2008544468 A JP2008544468 A JP 2008544468A JP 2009518422 A JP2009518422 A JP 2009518422A
Authority
JP
Japan
Prior art keywords
myostatin
binder
binding
independently
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008544468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518422A5 (enExample
Inventor
ハン，エイチキュー
デパオリ，アレキサンダー
ル，ジョン・ジャオ−ニアン
ワン，ジン・リン
Original Assignee
アムジェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジェン インコーポレイテッド filed Critical アムジェン インコーポレイテッド
Publication of JP2009518422A publication Critical patent/JP2009518422A/ja
Publication of JP2009518422A5 publication Critical patent/JP2009518422A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
JP2008544468A 2005-12-06 2006-12-06 ミオスタチン・アンタゴニストの使用 Pending JP2009518422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74273105P 2005-12-06 2005-12-06
PCT/US2006/046546 WO2007067616A2 (en) 2005-12-06 2006-12-06 Uses of myostatin antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012200485A Division JP2013028620A (ja) 2005-12-06 2012-09-12 ミオスタチン・アンタゴニストの使用

Publications (2)

Publication Number Publication Date
JP2009518422A true JP2009518422A (ja) 2009-05-07
JP2009518422A5 JP2009518422A5 (enExample) 2010-07-08

Family

ID=38123451

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008544468A Pending JP2009518422A (ja) 2005-12-06 2006-12-06 ミオスタチン・アンタゴニストの使用
JP2012200485A Pending JP2013028620A (ja) 2005-12-06 2012-09-12 ミオスタチン・アンタゴニストの使用
JP2014111126A Pending JP2014224115A (ja) 2005-12-06 2014-05-29 ミオスタチン・アンタゴニストの使用
JP2015235158A Pending JP2016094427A (ja) 2005-12-06 2015-12-01 ミオスタチン・アンタゴニストの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012200485A Pending JP2013028620A (ja) 2005-12-06 2012-09-12 ミオスタチン・アンタゴニストの使用
JP2014111126A Pending JP2014224115A (ja) 2005-12-06 2014-05-29 ミオスタチン・アンタゴニストの使用
JP2015235158A Pending JP2016094427A (ja) 2005-12-06 2015-12-01 ミオスタチン・アンタゴニストの使用

Country Status (7)

Country Link
US (3) US20070149458A1 (enExample)
EP (1) EP1968621A2 (enExample)
JP (4) JP2009518422A (enExample)
AU (3) AU2006321906C1 (enExample)
CA (2) CA2632544C (enExample)
MX (1) MX2008007324A (enExample)
WO (1) WO2007067616A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
HRP20130320T1 (en) * 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2315602A4 (en) 2008-06-26 2011-11-02 Acceleron Pharma Inc METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
AU2010204985A1 (en) * 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
PH12013500315A1 (en) * 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
WO2012151718A1 (zh) * 2011-05-11 2012-11-15 湖北省农业科学院畜牧兽医研究所 猪肌抑素基因启动子及其应用
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201591825A1 (ru) * 2013-03-15 2016-05-31 Амген Инк. Антагонизм миостатина у субъектов - людей
WO2014189475A1 (en) * 2013-05-24 2014-11-27 Alkoçlar Erdal Can A composition for treating the muscle weakness and the loss of muscle mass following chronic stroke and coma
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015134535A1 (en) * 2014-03-03 2015-09-11 Pinta Biotherapeutics, Inc. Combination therapy
WO2015187733A2 (en) * 2014-06-02 2015-12-10 Pinta Biotherapeutics, Inc. Myostatin inhibitors for treatment of diabetes
JP6568110B2 (ja) * 2014-06-04 2019-08-28 アクセルロン ファーマ， インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
MX2017007519A (es) * 2014-12-08 2017-08-22 Novartis Ag Antagonistas de miostatina o activina para el tratamiento de sarcopenia.
CA2980757A1 (en) * 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
US20180238915A1 (en) * 2015-08-18 2018-08-23 Massachusetts Institute Of Technology Microfluidic Platform For Rapid Biologics Analysis
US11357851B2 (en) * 2015-11-11 2022-06-14 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
TWI897843B (zh) 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
WO2018218273A1 (en) * 2017-05-29 2018-12-06 Paranta Biosciences Limited Method of treating hypertension and kidney disease
IL276921B2 (en) 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition
WO2025177263A1 (en) 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins
WO2025219859A1 (en) 2024-04-14 2025-10-23 Biohaven Therapeutics Ltd. Combination therapy to treat overweight, obesity, and related health conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058988A2 (en) * 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
WO2005032578A1 (en) * 2003-10-06 2005-04-14 Monash University Therapeutic method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
CA2157577C (en) * 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
EP1593689A3 (en) * 2000-01-18 2006-04-05 Ovita Limited Myostatin and mimetics thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
WO2004108157A2 (en) * 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
BRPI0406605B8 (pt) * 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8110665B2 (en) * 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
CA2558478A1 (en) * 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058988A2 (en) * 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
WO2005032578A1 (en) * 2003-10-06 2005-04-14 Monash University Therapeutic method

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6012013116; Ｍｕｄａｌｉ　Ｓ　ａｎｄ　Ｄｏｂｓ　ＡＳ．: 'Ｅｆｆｅｃｔｓ　ｏｆ　ｔｅｓｔｏｓｔｅｒｏｎｅ　ｏｎ　ｂｏｄｙ　ｃｏｍｐｏｓｉｔｉｏｎ　ｏｆ　ｔｈｅ　ａｇｉｎｇ　ｍａｌｅ．' Ｍｅｃｈ　Ａｇｅｉｎｇ　Ｄｅｖ． Ｖｏｌ．１２５　ｎｏ．４, 200404, ｐｐ．２９７-３０４ *
JPN6012013118; Ｇｏｒｄｏｎ　Ｓ　Ｌ: 'Ｕｐｄａｔｅ　ｏｎ　ｔｈｅｒａｐｉｅｓ　ｆｏｒ　ｓａｒｃｏｐｅｎｉａ：　ｎｏｖｅｌ　ａｐｐｒｏａｃｈｅｓ　ｆｏｒ　ａｇｅ-ｒｅｌａｔｅｄ　ｍｕｓｃｌｅ　ｗａｓｔｉｎｇ　ａｎｄ　ｗｅａｋｎｅｓｓ' Ｅｘｐｅｒｔ　Ｏｐｉｎｉｏｎ　ｏｎ　Ｔｈｅｒａｐｅｕｔｉｃ　Ｐａｔｅｎｔｓ Ｖｏｌ．１４　Ｎｏ．９, 200409, ｐｐ．１３２９-１３４４ *
JPN6012013121; Ｋｏｊｉｍａ　Ｉ　ｅｔ　ａｌ．: 'Ｒｏｌｅ　ｏｆ　ｔｈｅ　ａｃｔｉｖｉｎ-ｆｏｌｌｉｓｔａｔｉｎ　ｓｙｓｔｅｍ　ｉｎ　ｔｈｅ　ｍｏｒｐｈｏｇｅｎｅｓｉｓ　ａｎｄ　ｒｅｇｅｎｅｒａｔｉｏｎ　ｏｆ　ｔｈｅ　ｒｅｎａｌ　ｔｕｂｕｌｅｓ' Ｍｏｌｅｃｕｌａｒ　ａｎｄ　Ｃｅｌｌｕｌａｒ　Ｅｎｄｏｃｒｉｎｏｌｏｇｙ Ｖｏｌ．１８０　ｎｏ．１-２, 2001, ｐｐ．１７９-１８２ *
JPN6012013123; 前島明人ら: '腎の再生医学' 医学のあゆみ Ｖｏｌ．１９９　ｎｏ．１３, 20011229, ｐｐ．１１０７-１１１２ *
JPN6012013125; Ｄｏｈｉ　Ｔ　ｅｔ　ａｌ．: 'Ｔｈｅｒａｐｅｕｔｉｃ　ｐｏｔｅｎｔｉａｌ　ｏｆ　ｆｏｌｌｉｓｔａｔｉｎ　ｆｏｒ　ｃｏｌｏｎｉｃ　ｉｎｆｌａｍｍａｔｉｏｎ　ｉｎ　ｍｉｃｅ．' Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ． Ｖｏｌ．１２８　ｎｏ．２, 200502, ｐｐ．４１１-４２３ *

Also Published As

Publication number Publication date
MX2008007324A (es) 2009-03-04
AU2010214673A1 (en) 2010-09-16
AU2006321906B2 (en) 2010-09-09
CA2632544A1 (en) 2007-06-14
JP2016094427A (ja) 2016-05-26
AU2010214691A1 (en) 2010-09-16
CA2632544C (en) 2014-09-23
US20070149458A1 (en) 2007-06-28
JP2013028620A (ja) 2013-02-07
AU2010214673B2 (en) 2013-09-12
AU2006321906A1 (en) 2007-06-14
WO2007067616A3 (en) 2008-10-09
US20140294866A1 (en) 2014-10-02
EP1968621A2 (en) 2008-09-17
CA2856436A1 (en) 2007-06-14
AU2010214691B2 (en) 2013-09-12
AU2006321906C1 (en) 2014-01-16
WO2007067616A2 (en) 2007-06-14
JP2014224115A (ja) 2014-12-04
US20110008375A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
JP4959137B2 (ja) ミオスタチンを阻害する結合剤
JP2016094427A (ja) ミオスタチン・アンタゴニストの使用
JP2016516064A (ja) ヒト対象におけるミオスタチンの拮抗
AU2013213714A1 (en) Uses of myostatin antagonists
HK1152953A (en) Binding agents which inhibit myostatin
AU2016202981A1 (en) Binding agents which inhibit myostatin

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120608

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106